Press release - November 22nd, 2011

Cerbomed at the 7th annual meeting of the German Society of Neuromodulation

ERLANGEN/AACHEN, Germany, 22.11.2011 – the medical device company cerbomed presents the world’s first transcutaneous Vagus Nerve Stimulator NEMOS at the 7th annual meeting of the German Society of Neuromodulation on November 25th and 26th 2011.

Transcutaneous Vagus Nerve Stimulation (t-VNS) with NEMOS is based on the fact that branches of the vagus nerve are located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses. For t-VNS cerbomed developed and patented a special stimulator and a new type of ear electrode. The stimulator, which is connected with the ear electrode, sends out the electrical impulses.

The t-VNS therapy is addressed to patients suffering from various difficult to treat neurological and psychiatric diseases. With NEMOS a targeted stimulation of the brain gets possible without the need of a surgery.
The German market entry for NEMOS is planned for the third quarter of 2012. NEMOS will then be available for patients suffering from hard to treat epilepsies and depression.

About cerbomed
Cerbomed is an innovative medical device company that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus Nerve Stimulation (t-VNS), which offers an attractive therapy alternative for patients with hard to treat neurological and psychiatric illnesses.
In March 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus Nerve Stimulator NEMOS. In 2011 two clinical studies regarding the effectiveness of t-VNS in patients with drug-resistant epilepsies and chronic migraine will be starting.

pdf Download Article

Please note: NEMOS® is not cleared or approved for use in the U.S.